Active not recruiting
A Study of Baricitinib (LY3009104) in Adult Participants With Moderate to Severe Atopic Dermatitis (Eczema) (BREEZE-AD5)
I4V-MC-JAIW - ClinicalTrials.gov - NCT03435081
The purpose of this study is to evaluate the efficacy and safety of baricitinib in adult participants with moderate to severe eczema.
How long will I be in the trial?
Your participation could last up to 113 weeks and include up to 16 visits to the study center.
Active not recruiting
A Study of Baricitinib (LY3009104) in Adult Participants With Moderate to Severe Atopic Dermatitis (Eczema) (BREEZE-AD5)
I4V-MC-JAIW - ClinicalTrials.gov - NCT03435081
The purpose of this study is to evaluate the efficacy and safety of baricitinib in adult participants with moderate to severe eczema.
How long will I be in the trial?
Your participation could last up to 113 weeks and include up to 16 visits to the study center.
Key Requirements
Age :
18+
Sex:
All
Key Requirements
Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.
Age
18+
Sex
All
Participants must
Participants must have been diagnosed with moderate to severe eczema for at least 12 months
Participants must be willing to stop taking certain eczema treatments
Participants must agree to use a lotion or cream that softens the skin daily
Participants must NOT
Participants must not have had satisfactory results with existing medications applied to the skin
Participants must not have other skin conditions (such as psoriasis or lupus) or a history of skin diseases or infections that did not respond to treatment or require frequent hospitalization and/or IV treatment
Participants must not have a skin infection that requires antibiotics or are currently taking antibiotics that affect the whole body or are applied to the skin
Participants must not have been treated with corticosteroids corticosteroids given by injection within 6 weeks prior to treatment assignment and are not expected to need corticosteroid injections during the study
Participants must not have uncontrolled high blood pressure, major surgery (within the last two months or planned to take place during the study), or recent blood clot, heart attack, chest pain, stroke, heart failure or any other serious or unstable disease or infection - Female participants must not be pregnant or breastfeeding
Trial Summary
Conditions the trial is for
Atopic Dermatitis (Eczema)
What the trial is testing?
Baricitinib, Placebo
Could I receive a Placebo?
yes
Enrollment Goal
450
Trial Dates
February 2018 - September 2021
Trial Phase
3
Enter your postal code to find the nearest site
Key Requirements
Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.
Age
18+
Sex
All
Participants must
Participants must have been diagnosed with moderate to severe eczema for at least 12 months
Participants must be willing to stop taking certain eczema treatments
Participants must agree to use a lotion or cream that softens the skin daily
Participants must NOT
Participants must not have had satisfactory results with existing medications applied to the skin
Participants must not have other skin conditions (such as psoriasis or lupus) or a history of skin diseases or infections that did not respond to treatment or require frequent hospitalization and/or IV treatment
Participants must not have a skin infection that requires antibiotics or are currently taking antibiotics that affect the whole body or are applied to the skin
Participants must not have been treated with corticosteroids corticosteroids given by injection within 6 weeks prior to treatment assignment and are not expected to need corticosteroid injections during the study
Participants must not have uncontrolled high blood pressure, major surgery (within the last two months or planned to take place during the study), or recent blood clot, heart attack, chest pain, stroke, heart failure or any other serious or unstable disease or infection - Female participants must not be pregnant or breastfeeding
Trial Summary
Conditions the trial is for
Atopic Dermatitis (Eczema)
What the trial is testing?
Baricitinib, Placebo
Could I receive a Placebo?
yes
Enrollment Goal
450
Trial Dates
February 2018 - September 2021
Trial Phase
3
Not the right fit? Sign up to receive updates on new Atopic Dermatitis (Eczema) trials.
Trial Locations
Hide locations not currently recruiting
Enter your postal code to see sites near you
Atopic Dermatitis (Eczema) Resources
